Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature
Cristina Pirlog,Andreea Parosanu,Cristina Orlov Slavu,Mihaela Olaru,A.M. Popa,Cristian Iaciu,Irina Nita,Pompilia Motatu,Cotan Horia,Loredana Sabina Cornelia Manolescu,Cornelia Nitipir +10 more
TLDR
In this article , the authors sought to identify the answers to four questions: 1. what type of cancer has more severe hypersensitivity reactions to Nivolumab, 2. what is the time frame for developing these severe reactions to nivolumaab, 3. whether it is best to continue or stop the treatment after a severe hypersensitive reaction to NIVolumaba, and 4. what severe hypersensation reactions are the most frequent reported along Nivilumab treatment.Abstract:
Immune-checkpoint inhibitors (ICIs) are the most effective treatments nowadays. Nivolumab was the second ICI used for treating solid tumors with amazing results. Patients treated with Nivolumab may react differently to this treatment. Some people tolerate this treatment very well without experiencing any adverse reactions, whilst some may have mild symptoms and a part of them can present severe reactions. In our research, we sought to identify the answers to four questions: 1. what type of cancer has more severe hypersensitivity reactions to Nivolumab, 2. what is the time frame for developing these severe reactions to Nivolumab, 3. whether it is best to continue or stop the treatment after a severe hypersensitivity reaction to Nivolumab and 4. what severe hypersensitivity reactions are the most frequent reported along Nivolumab treatment. This review also highlights another problem with regard to the usage of concomitant and prior medications or other methods of treatment (e.g., radiation therapy), which can also lead to severe reactions. Treatment with Nivolumab is very well tolerated, but patients should also be warned of the possibility of severe hypersensitivity reactions for which they should urgently see a doctor for a personalized evaluation. There are some options for individuals with severe hypersensitivity reactions, for eg. switching the medication or applying a desensitization protocol.read more
Citations
More filters
Journal ArticleDOI
The Bidirectional Relationship between Pulmonary Tuberculosis and Lung Cancer
Mădălina Preda,Bogdan Tănase,Daniela Zob,Adelina Silvana Gheorghe,Cristian Virgil Lungulescu,E. Dumitrescu,Dana Lucia Stănculeanu,Loredana Sabina Cornelia Manolescu,Oana Popescu,Elmira Ibraim,Beatrice Mahler +10 more
TL;DR: In this paper , pulmonary rehabilitation is recommended for post-tuberculosis patients and lung cancer patients and should be recommended to improve outcomes in these pathologies, which may lead to the reactivation of latent tuberculosis infection.
Journal ArticleDOI
Advances in Alpha Herpes Viruses Vaccines for Human
TL;DR: A trivalent vaccine containing herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, GD2, gE2) produced in baculovirus was able to protect guinea pigs against vaginal infection and proved to cross-protect against HSV-1 as discussed by the authors .
Journal ArticleDOI
Immediate hypersensitivity reactions to antineoplastic agents - A practical guide for the oncologist.
Sofie Seghers,Laure Anne Teuwen,M. Beyens,Dennis De Blick,Vito Sabato,Didier G. Ebo,Hans Prenen +6 more
TL;DR: In this paper , the authors reviewed the definition, pathophysiology, epidemiology, diagnosis and management of immediate hypersensitivity reactions (IHRs) to antineoplastic agents and monoclonal antibodies.
References
More filters
Journal ArticleDOI
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf,Florin-Andrei Taran,Markus Wallwiener,Christina B. Walter,Bernhard K. Krämer,Eva-Maria Grischke,Sara Y. Brucker +6 more
TL;DR: This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Journal ArticleDOI
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
Rimda Wanchoo,Sabine Karam,Nupur N. Uppal,Valerie S. Barta,Gilbert Deray,Craig Devoe,Vincent Launay-Vacher,Kenar D. Jhaveri +7 more
TL;DR: Although initially thought to be rare, the incidence rates of renal toxicities might be higher as identified by recent studies, Steroids appear to be effective in treating the immune-related adverse effects noted with these agents.
Journal ArticleDOI
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Koji Haratani,Hidetoshi Hayashi,Yasutaka Chiba,Keita Kudo,Kimio Yonesaka,Ryoji Kato,Hiroyasu Kaneda,Yoshikazu Hasegawa,Kaoru Tanaka,Masayuki Takeda,Kazuhiko Nakagawa +10 more
TL;DR: Development of irAEs was associated with survival outcome of nivolumab treatment in patients with advanced or recurrent NSCLC, andMultivariable analysis revealed that iraes were positively associated with Survival outcome, with hazard ratios of 0.525 and 0.282.
Related Papers (5)
Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin.
Mauro Pagani,Patrizia Bonadonna +1 more